Clin Osteol 2025; 30(4): 203-208

Management of osteoporosis in childrenReview articles

Ľubica Tichá, Ľudmila Podracká
Detská klinika LF UK a NÚDCH Bratislava, Slovensko

Osteoporosis in childhood is a rare but serious condition characterized by reduced bone density and increased susceptibility to fractures. Primary (genetically determined) disorders account for only a small proportion of cases, while up to 98% develop secondarily in association with another underlying disease. Diagnosis is based on clinical presentation, fracture history, and measurement of bone mineral density using Dual Energy X-ray Absorptiometry (DXA). In children, it is essential to adjust the Z-score for current height to ensure accurate interpretation of the results. Treatment requires a multidisciplinary approach focused on managing the underlying condition, optimizing nutrition, promoting physical activity, and, when indicated, administering medications that improve bone quality. This article provides an overview of current diagnostic and therapeutic recommendations, highlights differences compared to adult patients, and emphasizes the need for individualized management.

Keywords: osteoporosis, children, diagnostics, treatment, bone mineral density.

Published: December 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tichá Ľ, Podracká Ľ. Management of osteoporosis in children. Clinical Osteology. 2025;30(4):203-208.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 1.12.2026

    References

    1. Clark EM. The epidemiology of fractures in otherwise healthy children. Curr Osteoporos Rep. 2014;12(3):272-8. doi: 10.1007/s11914-014-0227-y. Go to original source...
    2. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657-1671. doi: 10.1016/S0140-6736(15)00728-X. Go to original source...
    3. Zemel BS, Leonard MB, Kelly A, et al. Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95(3):1265-1273. doi: 10.1210/jc.2009-2057. Go to original source...
    4. Crabtree NJ, Arabi A, Bachrach LK. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014;17(2):225-227. doi: 10.1016/j.jocd.2014.01.003. Go to original source...
    5. Bianchi ML. Osteoporosis in children and adolescents. Bone. 2007;41(4):486-495. doi:10.1210/jc.2007-0828. Go to original source...
    6. Gordon CM, Leonard MB and Zemel BS. 2013, Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 2014;17:219-224.
    7. Official Pediatric Positions of the ISCD as updated in 2019.https://iscd.org/wp-content/uploads/2021/09/2019-Official-Positions-Pediatric-1.pdf.
    8. Ward LM. A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence. Frontiers in Endocrinology. 2024;14:1266986.
    9. Crabtree NJ, Chapman S, Högler W, et al. Vertebral fractures assessment in children: Evaluation of DXA imaging versus conventional spine radiography. Boneo 2017;97:168-174.
    10. Verdonk SJE,et al. Medical Care Use Among Patients with Monogenic Osteoporosis Due to Rare Variants in LRP5, PLS3, or WNT1. Calcif Tissue Int. 2023 Aug;113(2):186-194. doi: 10.1007/s00223-023-01101-3. Go to original source...
    11. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Rev Drug Discov. 2013;12(5):351-370.
    12. Sam JE, Dharmalingam M. Osteogenesis Imperfecta. Indian J Endocrinol Metab. 2017; 21(6):903-908. doi: 10.4103/ijem.IJEM_220_17. Go to original source...
    13. Hasegawa K. Osteogenesis imperfecta: pathogenesis, classification, and treatment. Clin Pediatr Endocrinol. 2025;34(3):152-161.
    14. Günay A., Turan S. Pediatric osteoporosis. An update Trends in Pediatrics 2024;5(4):105-115.
    15. Frost HM. Bone & quot;mass & quot; and the & quot;mechanostat & quot: a proposal. Anat Rec. 1987;219(1):1-9. doi: 10.1002/ar.1092190104. Go to original source...
    16. Ward LM, et al. Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. J Bone Miner Res. 2018;33(8):1435-1443. doi: 10.1002/jbmr.3447. Go to original source...
    17. Alos N, Grant R, Ramsay T, et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol. 2012;1;30(22):2760-7. doi: 10.1200/JCO.2011.40.4830. Go to original source...
    18. Sakka SD, Cheung MS. Management of primary and secondary osteoporosis in children. Ther Adv Musculoskelet Dis. 2020 Nov 2;12:1759720X20969262. doi:10.1177/1759720X20969262. Go to original source...
    19. Bayer M. Osteogenesis imperfecta - state of art. Čes‑slov Pediatr. 2017;72(4):212-222.
    20. Kutílek Š, Plášilová I, Skálová S, et al. Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta. Acta Medica (Hradec Králové). 2021;64(3):187-192. doi:10.14712/18059694.2021.32. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.